April 7, 2022 -- Genethon has joined the U.S.-based Bespoke Gene Therapy Consortium (BGTC) launched by the Foundation for the National Institutes of Health, as part of its Accelerating Medicines Partnership program.
Genethon is a nonprofit gene therapy R&D organization founded by the French Muscular Dystrophy Association and is so far the only European organization in the consortium.
The consortium is a public-private partnership among the National Institutes of Health and the U.S. Food and Drug Administration with biopharmaceutical companies and other nonprofit groups to develop new gene therapies for rare diseases.
BGTC focuses on basic research, clinical research, bioproduction, and regulatory requirements for rare diseases.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
